+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Car T Therapies"

From
From
From
Innovation Insights: B-cell Depletion - Product Thumbnail Image

Innovation Insights: B-cell Depletion

  • Report
  • December 2024
  • 55 Pages
  • Global
From
From
From
From
Cancer Immunotherapy - A Global Market Overview - Product Thumbnail Image

Cancer Immunotherapy - A Global Market Overview

  • Report
  • November 2024
  • 256 Pages
  • Global
From
Immuno-Oncology Clinical Trials Market Report 2023-2033 - Product Thumbnail Image

Immuno-Oncology Clinical Trials Market Report 2023-2033

  • Report
  • September 2023
  • 249 Pages
  • Global
From
PSMA - Targeted Therapy Pipeline Review - Product Thumbnail Image

PSMA - Targeted Therapy Pipeline Review

  • Report
  • April 2025
  • Global
From
From
From
From
Loading Indicator

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer. Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer. Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more